Partner David Rosen participated in a question and answer session with Reuter’s Westlaw, “Q&A: Foley & Lardner’s David Rosen on Obstacles to Generic EpiPen,” on October 24, 2106. The article discussed obstacles to getting a generic version of Mylan’s EpiPen on the market and how the U.S. Food and Drug Administration (FDA) can hasten the process.
In response to whether or not the FDA can help generic products reach the market, Rosen said, “They could facilitate them by having a little bit more interaction with the applicants, i.e., allowing them to come in for a meeting so they can address the issues and concerns with the developmental process and so they can understand FDA’s expectations. That will also help FDA understand and appreciate the developmental work that’s being done. Companies can get a little more guidance on what they’re doing and how they can meet FDA’s expectations for approval.”
In response to whether or not the FDA can help generic products reach the market, Rosen said, “They could facilitate them by having a little bit more interaction with the applicants, i.e., allowing them to come in for a meeting so they can address the issues and concerns with the developmental process and so they can understand FDA’s expectations. That will also help FDA understand and appreciate the developmental work that’s being done. Companies can get a little more guidance on what they’re doing and how they can meet FDA’s expectations for approval.”
People
Related News
14 February 2025
In the News
Brian Wheeler Joins Podcast to Discuss Legal Journey
Foley & Lardner LLP partner Brian Wheeler joined the Hsu Untied podcast to discuss his legal career.
14 February 2025
In the News
Pavan Agarwal Featured in Leadership Q&A – 'Reflecting our firm’s core values drives me to do my best'
Foley & Lardner LLP partner Pavan Agarwal is featured by Law.com for his career journey, legal practice, and leadership in the article, “How I Made Practice Group Chair: ‘Keep Listening and Keep Learning,’ Says Pavan Agarwal of Foley & Lardner.”
14 February 2025
In the News
Judith Waltz on Trump Administration Deregulation Order, Impact on CMS
Foley & Lardner LLP partner Judith Waltz commented on the Trump administration's executive order requiring federal agencies cut ten regulations for each newly created one in the Modern Healthcare article, "CMS may evade Trump's sweeping deregulation order."